Compositions for enhancing delivery of CGRP inhibitors
Patent Information
- Application Number
- JP2023529881
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-17
- Filing Date
- 2021-11-18
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing pharmaceutical compositions with CGRP inhibitors suffer from low oral bioavailability and can be irritating to mucous membranes, necessitating the development of non-toxic, non-irritating surfactants that enhance bioavailability without compromising membrane integrity.
The use of carbohydrate surfactants, such as alkyl glycosides and carbohydrate esters, in combination with CGRP inhibitors to form rapidly dispersing dosage forms that enhance absorption and reduce first-pass metabolism.
The compositions increase the bioavailability of CGRP inhibitors, leading to faster drug action onset and reduced recurrence of migraine pain, while being non-toxic and non-irritating to mucosal surfaces.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical Field]
[0001] Cross-references to related applications This application claims priority to U.S. Provisional Patent Application No. 63 / 115,789 filed November 19, 2020, and U.S. Provisional Patent Application No. 63 / 126,550 filed December 17, 2020, and all benefits arising from these provisional patent applications under Section 119 of the U.S. Patent Act (35 U.S.SC), the contents of which are incorporated herein by reference in their entirety.
[0002] This invention relates to a non-irritating, non-toxic composition that enhances the bioavailability of effective therapeutic components. Specifically, this invention relates to a composition containing a carbohydrate surfactant for delivering a calcitonin gene-related peptide (CGRP) inhibitor to a target, and a method of using the same. [Background technology]
[0003] CGRP inhibitors are often combined with various surfactants in pharmaceutical compositions. However, some compositions have low oral bioavailability, resulting in insufficient delivery of CGRP inhibitors. Furthermore, some surfactants can be irritating to mucous membranes. An ideal bioavailability-enhancing surfactant would be non-toxic and non-irritating to the skin or mucous membrane surface, enhancing the passage or absorption of CGRP inhibitors across the membrane barrier without impairing the structural integrity and biological function of the membrane, thereby improving the bioavailability of the effective therapeutic component. [Overview of the project] [Problems that the invention aims to solve]
[0004] Several methods have been described for manufacturing rapidly disintegrating, or so-called "rapidly dispersible," dosage forms. After disintegration in the oral cavity, the drug substance is swallowed, resulting in pregastric and ultimately gastric absorption. Previously described rapidly dispersible dosage forms provide formulations that disintegrate or dissolve when placed in the mouth to promote pregastric or gastric absorption of the active ingredient. However, there is still a need for novel rapidly dispersible dosage forms that improve properties such as accelerating the onset of drug action and reducing first-pass effect drug metabolism. [Means for solving the problem]
[0005] This invention relates to pharmaceutical compositions and methods for improving the bioavailability of calcitonin gene-related peptide (CGRP) inhibitors.
[0006] One embodiment provides a pharmaceutical composition comprising a CGRP inhibitor and a carbohydrate surfactant in an amount that increases absorption.
[0007] Another embodiment provides a pharmaceutical composition comprising a CGRP inhibitor and an amount of a carbohydrate surfactant that increases absorption, in the form of an oral solid molded fast-dispersing dosage form.
[0008] Another embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of zavegepant, its solvate, or a pharmaceutically acceptable salt thereof, in the form of a solid-molded oral rapidly dispersible dosage form.
[0009] Another embodiment provides a method for increasing the bioavailability of a CGRP inhibitor in a subject, comprising orally administering one of the above-mentioned pharmaceutical compositions.
[0010] Another embodiment provides a method for treating migraines in a subject requiring such treatment, comprising orally administering one of the above-mentioned pharmaceutical compositions to the subject.
[0011] Another embodiment provides a method for providing a rapid onset of relief of migraine pain in a subject that needs it, the method comprising orally administering to the subject any of the pharmaceutical compositions described above.
[0012] Another embodiment provides a method for reducing the incidence of recurrence of migraine pain in a subject that needs it, the method comprising orally administering to the subject any of the pharmaceutical compositions described above.
[0013] Another embodiment provides a method for treating or preventing a condition associated with abnormal levels of CGRP in a subject that needs it, the method comprising administering to the subject any of the pharmaceutical compositions described above.
[0014] These and / or other aspects will become apparent and be more readily appreciated by reference to the following description of the embodiments in conjunction with the accompanying drawings.
Brief Description of the Drawings
[0015] [Figure 1] It is a graph showing plasma concentration (nanograms per milliliter, ng / mL) versus time (hours, hr) showing the average BHV-3500 concentration (ng / mL) in the plasma of dogs after administration of a single 50 milligram (mg) sublingual tablet.
Modes for Carrying Out the Invention
[0016] The following detailed description is provided to assist those skilled in the art in practicing the present invention. Exemplary embodiments are described in detail below. However, these embodiments are merely exemplary and the present disclosure is not limited thereto, but rather is defined by the appended claims. Those skilled in the art can make modifications and variations to the embodiments described herein without departing from the spirit or scope of the present disclosure.
[0017] Therefore, to describe the embodiments herein, the embodiments will be simply described below by referring to the structures and schemes. As used herein, the term "and / or" includes any and all combinations of one or more of the associated listed items. The term "or" means "and / or". Expressions such as "at least one of" when following a list of elements modify the entire list of elements and not the individual elements of the list.
[0018] When an element is referred to as being "on" another element, it will be understood that the element may be in direct contact with the other element or intervening elements may be present. In contrast, when an element is referred to as being "directly on" another element, no intervening element is present.
[0019] In this specification, terms such as first, second, third, etc. can be used to describe various elements, components, regions, layers, and / or sections, but it will be understood that these elements, components, regions, layers, and / or sections should not be limited by these terms. These terms are only used to distinguish one element, component, region, layer, or section from another element, component, region, layer, or section. Thus, the first element, component, region, layer, or section discussed below can be referred to as the second element, component, region, layer, or section without departing from the teachings of this embodiment.
[0020] The terms "comprises" and / or "comprising", or "includes" and / or "including", as used herein, define the presence of the described features, regions, compositions, steps, operations, elements, and / or components, but do not preclude the presence or addition of one or more other features, regions, compositions, steps, operations, elements, components, and / or groups thereof.
[0021] Unless otherwise defined, all terms and scientific terms used herein have the same meaning as those generally understood by those skilled in the art to which this disclosure belongs. The terminology used herein is solely for the purpose of describing specific embodiments and is not intended to be limiting. Terms such as those defined in commonly used dictionaries should be interpreted as having the meaning consistent with their meanings in the context of the relevant art and this disclosure, and it will be further understood that they should not be interpreted in an ideal or overly formal sense unless explicitly defined herein.
[0022] As used in this application, unless expressly otherwise provided herein, each of the following terms shall have the meaning set forth below. Additional definitions are provided throughout this application. If a term is not specifically defined herein, it shall be given the meaning recognized by a person skilled in the art applying the term in context to describe the invention.
[0023] The articles “a” and “an” refer to one or more (i.e., at least one) grammatical objects of the article, unless the context explicitly indicates otherwise. For example, “an element” means one or more elements.
[0024] In this specification, unless otherwise provided, the term “substituted” means a substituent or a group in which at least one hydrogen of a compound is substituted with deuterium, halogens (-F, -Cl, -Br, -I), hydroxyl groups (-OH), amino groups (-NH2), carboxyl groups (-CO2H), substituted or unsubstituted C1-C10 amine groups, nitro groups (-NO2), C1-C10 alkyl groups, C3-C10 cycloalkyl groups, C6-C12 aryl groups, C1-C10 alkoxy groups, C1-C10 trifluoroalkyl groups such as trifluoromethyl groups (-CF3), or cyano groups (-CN).
[0025] The starting materials useful for preparing the pharmaceutical compositions of the present invention are readily available commercially or can be prepared by those skilled in the art.
[0026] Additional aspects are described in part below, and some will become clear from the description.
[0027] Embodiments of the present invention relate to compositions for improving the delivery of CGRP inhibitors to a target and methods for using the same. One embodiment provides a pharmaceutical composition comprising a calcitonin gene-related peptide (CGRP) receptor antagonist and a carbohydrate surfactant in an amount that increases absorption.
[0028] CGRP inhibitors The compositions according to embodiments of the present invention include a calcitonin gene-related peptide (CGRP) inhibitor. As used herein, the term “CGRP inhibitor” refers to a chemical substance that may be an inhibitor of a CGRP ligand or a CGRP receptor. Therefore, the term “CGRP inhibitor” encompasses CGRP receptor inhibitors. CGRP (calcitonin gene-related peptide) is a 37-amino acid neuropeptide and belongs to a family of peptides that includes calcitonin, adremedullin, and amylin. Substantial evidence has been collected showing that CGRP is involved in the pathophysiology of migraine. Clinical trials have been conducted to demonstrate that CGRP inhibitors are effective in treating migraine. Following the clinical trials, several CGRP inhibitors have been approved by regulatory authorities and are marketed for the treatment of acute migraine and the prevention of migraine.
[0029] CGRP inhibitors may include CGRP antibodies, CGRP receptor antibodies, antigen-binding fragments from CGRP antibodies or CGRP receptor antibodies, CGRP injection inhibitor proteins, CGRP reactivators, small molecule CGRP receptor antagonists, small molecule CGRP inhibitors, or polypeptide CGRP inhibitors.
[0030] CGRP inhibitors can be CGRP receptor antagonists. The CGRP receptor antagonists according to the present invention are preferably non-biological CGRP antagonists. That is, the non-biological CGRP receptor antagonists of the present invention preferably do not contain antibodies, antibody fragments, or peptides. CGRP receptor antagonists can be small molecule receptor antagonists. Preferably, the small molecule CGRP receptor antagonists according to the present invention contain molecules having a mass of less than about 900 daltons, for example, less than about 800 daltons, less than about 700 daltons, less than about 600 daltons, less than about 500 daltons, less than about 400 daltons, or less than about 300 daltons. Examples of such non-biological CGRP antagonists include rimegepant, zabegepant, ubrogepant, atogepant, terkagepant, and orsegepant. In one embodiment, the low molecular weight CGRP receptor antagonist may be (R)-N-(3-(7-methyl-1H-indazole-5-yl)-1-(4-(1-methylpiperidine-4-yl)piperazine-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinoline-3-yl)piperidine-1-carboxamide (zabegepant).
[0031] Rimegepant has the chemical formula C 28 H 28 It has the IUPAC name [(5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-9-yl]4-(2-oxo-3H-imidazo[4,5-b]pyridine-1-yl)piperidine-1-carboxylate. Rimegepant is also known as BHV-3000, and is referred to as BHV-3000 herein.
[0032] The structure of the rimegepant is as follows:
[0033] [ka]
[0034] Limegepant is described, for example, in WO2011 / 046997, published on April 21, 2011. In a preferred embodiment of the present invention, limegepant exists in the form of a hemisulfate sesquihydrate salt. This preferred salt form is described in WO2013 / 130402, published on September 6, 2013.
[0035] The chemical formula for the salt form is C 28 H 28 The compound is F2N6O3·0.5H2SO4·1.5H2O, and its structure is as follows.
[0036] [ka]
[0037] Another CGRP antagonist is zabegepant (also known as BHV-3500), described in WO2011 / 123232, published on October 6, 2011, and has the following structure.
[0038] [ka]
[0039] Another CGRP antagonist is ubrogepant, which has the following structure.
[0040] [ka]
[0041] Another CGRP antagonist is an atgepant, which has the following structure.
[0042] [ka]
[0043] Another CGRP antagonist is terkagepant, which has the following structure.
[0044] [ka]
[0045] Another CGRP antagonist is the orsegepant, which has the following structure.
[0046] [ka]
[0047] CGRP inhibitors may have low oral bioavailability. Low oral bioavailability may be ≤80%, ≤75%, ≤70%, ≤65%, ≤60%, ≤55%, ≤50%, ≤45%, ≤40%, ≤35%, ≤30%, ≤25%, ≤20%, ≤15%, ≤10%, or ≤5%.
[0048] The compositions described herein may contain 1 to 1000 mg of a CGRP inhibitor. For example, a composition may contain about 1, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 200, 250, 300, 400, 500, 600, 700, 800, or 900 mg of a CGRP inhibitor. The amount of the CGRP inhibitor may be in the range between any of the above values.
[0049] CGRP inhibitors can be administered in doses of approximately 1 to 1000 mg per day. In another embodiment, CGRP inhibitors are administered in doses of approximately 1, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 200, 250, 300, 400, 500, 600, 700, 800, or 900 mg per day. The daily dose of CGRP inhibitors may be within the range of any of the above values. Compositions containing CGRP inhibitors can be administered as a single dose.
[0050] CGRP inhibitors can be administered for at least one week and for as long as necessary. For example, CGRP inhibitors can be administered for one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve weeks.
[0051] Carbohydrate surfactants The composition further contains a carbohydrate surfactant in an amount that increases absorption. As used herein, “carbohydrate” includes linear or cyclic monocarbohydrates, oligocarbohydrates, or polycarbohydrates, or combinations thereof that form a carbohydrate chain. Oligocarbohydrates are carbohydrates having two or more but less than 100 monohydrate residues. Polycarbohydrates contain 100 or more monohydrate residues. Carbohydrates may be selected from, for example, any monocarbohydrate species currently on the market, or may be synthesized. Some examples of the many possible carbohydrates to use include glucose, maltose, maltotriose, maltotetraose, sucrose, and trehalose. Preferred carbohydrates include maltose, sucrose, and glucose.
[0052] In one embodiment, the carbohydrate surfactant may be an alkyl glycoside. As used herein, the term “alkyl glycoside” refers to any carbohydrate linked by any hydrophobic alkyl by bonding, as is known in the art. The alkyl glycoside is preferably non-toxic and non-ionic and, when administered with the compound via oral, ocular, nasal cavity, nasolacrimal duct, nose to brain, inhalation or lung, oral cavity (sublingual or buccal cells), or cerebrospinal fluid (CSF) delivery routes, increases the absorption of the CGRP inhibitor. A suitable compound can be determined using the method described herein.
[0053] The alkyl glycosides disclosed herein can be synthesized by known procedures, namely, chemically, for example, by the procedures described in Rosevear et al., Biochemistry 19:4108-4115 (1980) or Koeltzow and Urfer, J. Am. Oil Chem. Soc., 61:1651-1655 (1984), U.S. Patents No. 3,219,656 and 3,839,318, or enzymatically, for example, by the procedures described in Li et al., J. Biol. Chem., 266:10723-10726 (1991) or Gopalan et al., J. Biol. Chem. 267:9629-9638 (1992).
[0054] The alkyl glycosides of the present invention include alkyl glycosides, such as octyl-, nonyl-, decyl-, undecyl-, dodecyl-, tridecyl-, tetradecyl-, pentadecyl-, hexadecyl-, heptadecyl-, and octadecyl-α- or β-D-maltoside, glucoside, or sucrose (synthesized according to Koeltzow and Urfer; Anatrace Inc., Maumee, Ohio; Calbiochem, San Diego, Calif.; Fluka Chemie, Switzerland); and alkyl thiomaltosides, such as heptyl-, octyl-, dodecyl-, tridecyl-, and tetradecyl-β-D-thiomaltoside (Defaye, J. and Pederson, C., "Hydrogen Fluoride, Solvent and Reagent for Carbohydrate Conversion Technology" in Carbohydrates as Organic Raw). Materials, 247-265 (FW L. Chtenthaler ed.), VCH Publishers, New York (1991); synthesized according to Ferenci, T., J. Bacteriol, 144:7-11 (1980); alkylthioglucosides, e.g., heptyl- or octyl 1-thio-α- or β-D-glucopyranoside (see Anatrace, Inc., Maumee, Ohio; Saito, S. and Tsuchiya, T., Chem. Pharm. Bull. 33:503-508 (1985)); alkylthiosucrose (e.g., Binder, TP. and Robyt, JF., Carbo Synthesized according to hydr.Res.140:9~20 (1985); alkylmaltotriosides (synthesized according to Koeltzow and Urfer); long-chain aliphatic carbonate amides of sucrose β-amino-alkyl ethers; (synthesized according to Austrian Patent Nos. 382, 381 (1987); Chem.Abstr., 108:114719 (1988) and Gruber and Greber, pp. 95~116); derivatives of palatinose and isomaltamine linked to alkyl chains by amide bonds (Kunz, M.Examples include, but are not limited to, those synthesized according to "Sucrose-based Hydrophilic Building Blocks as Intermediates for the Synthesis of Surfactants and Polymers" in Carbohydrates as Organic Raw Materials, pp. 127-153; derivatives of isomaltamine bonded to alkyl chains by urea (synthesized according to Kunz); long-chain aliphatic carbonate ureids of sucrose β-amino-alkyl ethers (synthesized according to Gruber and Greber, pp. 95-116); and long-chain aliphatic carbonate amides of sucrose β-amino-alkyl ethers (synthesized according to Austrian Patent Nos. 382, 381 (1987), Chem. Abstr., 108:114719 (1988), and Gruber and Greber, pp. 95-116).
[0055] In another embodiment, the carbohydrate surfactant may be a carbohydrate ester. As used herein, the term “carbohydrate ester” refers to a carbohydrate ester of any fatty acid. Carbohydrate esters can take many forms because several hydroxyl groups in the carbohydrate are available for reaction, and there are many fatty acid groups, from acetates to larger, bulkier fatty acids that can react with carbohydrates. This flexibility means that many products and functionalities can be tailored based on the fatty acid portion used. Carbohydrate esters have food and non-food applications, particularly as surfactants and emulsifiers, and their use is expanding in pharmaceuticals, cosmetics, detergents, and food additives. They are biodegradable, non-toxic, and low in skin irritation. In one embodiment, the carbohydrate ester may be a sucrose ester.
[0056] The carbohydrate surfactants disclosed herein may have a hydrophobic alkyl group bonded to a hydrophilic carbohydrate. Examples of bonds between the hydrophobic alkyl group and the hydrophilic carbohydrate include, in particular, glycosidic bonds, thioglycosidic bonds (Horton), amide bonds (Carbohydrates as Organic Raw Materials, edited by FWLichtenthaler, VCH Publishers, New York, 1991), ureid bonds (Austrian Patent No. 386,414 (1988); Chem. Abstr. 110:137536p (1989); Gruber, H. and Greber, G., "Reactive Sucrose Derivatives" in Carbohydrates as Organic Raw Materials, pp. 95-116), or ester bonds (Sugar Esters: Preparation and Application, edited by JCColbert (Noyes Data Corp., New Jersey), (1974)). Furthermore, preferred glycosides include, but are not limited to, maltose, sucrose, and glucose linked to an alkyl chain of about 9 to 16 carbon atoms by glycosidic bonds, such as nonyl, decyl, dodecyl, and tetradecyl sucrose, glucosides, and maltosides. These compositions are amphiphilic and nontoxic because they decompose into alcohols and oligocarbohydrates.
[0057] In another embodiment, a carbohydrate surfactant may include alkyl glycosides and / or carbohydrate esters having a characteristic hydrophilic-lipophilic balance (HLB) value that can be determined by calculation or empirically (Schick, MJ, Nonionic Surfactants, p. 607 (New York: Marcel Dekker, Inc. 1967)). The HLB value directly reflects the hydrophilic characteristics of the surfactant; that is, the higher the HLB value, the more hydrophilic the compound. The HLB value can be calculated by the following formula: (20 × MW hydrophilic component) / (MW hydrophobic component + MW hydrophilic component), where MW = molecular weight (Rosen, MJ, Surfactants and Interfacial Phenomena, pp. 242-245, John Wiley, New York (1978)). The HLB value directly expresses the hydrophilicity of the surfactant; that is, the higher the HLB value, the more hydrophilic the compound. Carbohydrate surfactants can have an HLB value of about 10-20, for example, about 11-15.
[0058] As described above, the hydrophobic alkyl can be selected to any desired size depending on the desired hydrophobicity and hydrophilicity of the carbohydrate moiety. In one embodiment, the alkyl chain may range from about 9 to about 24 carbon atoms, for example, about 9 to about 16 or about 14 carbon atoms. Some glycosides include, but are not limited to, maltose, sucrose, and glucose linked by glycosidic bonds to alkyl chains of 9, 10, 12, 13, 14, 16, 18, 20, 22, or 24 carbon atoms, such as nonyl, decyl, dodecyl, and tetradecyl sucrose, glucosides, and maltosides. These compositions are nontoxic and amphiphilic, as they decompose into alcohols and oligocarbohydrates.
[0059] The above examples illustrate the types of glycosides used in the claimed inventions herein, but do not exhaust the list. Derivatives of the above compounds that meet the criteria of the claims should also be considered when selecting glycosides. All compounds can be screened for efficacy according to the methods taught herein and in the examples.
[0060] Formulation and method of administration Compositions according to embodiments of the present invention can be administered as tablets, capsules, suppositories, drops, sprays, or aerosols. Compositions can be administered as orally rapidly disintegrating tablets. Compositions can also be administered in sustained-release or delayed-burst form. Spray and aerosol administration can be achieved by using appropriate dispensers. Sustained-release forms may include ophthalmic implants, erosive microparticles, swollen mucosal-adhering microparticles, pH-sensitive microparticles, nanoparticle / latex systems, ion-exchange resins, and other polymer gels and implants (Ocusert, Alza Corp., California; Joshi, A., S. Ping and K.J. Himmelstein, WO91 / 19481). These systems maintain prolonged drug contact with the absorption surface to prevent leaching and unproductive drug loss. Prolonged drug contact is nontoxic to skin and mucous membrane surfaces.
[0061] The compositions disclosed herein are stable. For example, Baudys et al., in U.S. Patent No. 5,726,154, demonstrated that calcitonin in an aqueous liquid composition containing SDS (sodium dodecyl sulfate, a surfactant) and an organic acid is stable for at least six months. Similarly, the surfactant compositions of the present invention exhibit improved stabilization properties when mixed with CGRP inhibitors. Organic acids are not required in these formulations. For example, the compositions can maintain the stability of CGRP inhibitors for about six months or longer when maintained at approximately 4°C to 25°C.
[0062] The stability of the compositions disclosed herein is, in part, due to their high No Observed Adverse Effect Levels (NOAELs). The Environmental Protection Agency (EPA) defines a NOAEL as the level of exposure to which there is no statistically or biologically significant increase in the frequency or severity of adverse effects between an exposed population and a suitable control. Thus, the term “No Observed Adverse Effect Level” (or NOAEL) is the maximum concentration or amount of a substance found experimentally or observationally that, under defined conditions, does not cause any detectable adverse change to the morphology, functional capacity, growth, development, or lifespan of a target organism.
[0063] The World Health Organization (WHO) and the Food and Agriculture Organization of the United Nations (FAO) have shown that several alkyl glycosides have very high NOAELs, and therefore, increased intake of these alkyl glycosides is possible without any adverse effects. This report can be found on the World Wide Web at inchem.org / documents / jecfa / jecmono / v10je11.htm. For example, the NOAEL of sucrose dodecanoate, a type of sucrose ester used in food, is about 20-30 g / kg / day, meaning that a person weighing 70 kg (about 154 pounds) can consume about 1400-2100 g (or about 3-4.6 pounds) of sucrose dodecanoate per day without any observable adverse effects. Typically, the acceptable daily intake for humans is about 1% of the NOAEL, which corresponds to about 14-21 g per day, or 14 million-21 million μg, indefinitely. The definition of NOAEL and other related definitions can be found on the World Wide Web at epa.gov / OCEPAterms. Therefore, while some effects may occur at the alkyl glycoside levels expected in this invention, those levels are not considered harmful or a precursor to adverse effects.
[0064] Therefore, subjects treated with a composition according to an embodiment of the present invention, having at least one alkyl glycoside, for example tetradecyl maltoside (TDM; or Intravail A), at a concentration of about 0.125% by weight of the alkyl glycoside, twice a day, three times a day, or more times depending on the treatment regimen, will ingest a total of about 200-300 μg of TDM per day. Thus, the effective dose of TDM is at least 1 / 100 (i.e., 1 / 1000) of the NOAEL, and is far less than 1% of the NOAEL, which is the acceptable daily intake, or in this case, 1 / 50,000 of the acceptable daily intake. In other words, the alkyl glycosides disclosed herein have a high NOAEL such that the amount or concentration of alkyl glycoside used does not cause adverse effects and can be safely ingested without any adverse effects.
[0065] Compositions according to embodiments of the present invention are also stable because they are physiologically non-toxic and non-irritating. As used herein, the term “non-toxic” means that the alkyl glycoside molecule has sufficiently low toxicity to be suitable for administration and ingestion to humans. Preferred alkyl glycosides are non-irritating to the tissues to which they are applied. Any alkyl glycoside used should have minimal or no toxicity to cells so as not to cause cell damage. However, the toxicity to any given alkyl glycoside may vary depending on the concentration of alkyl glycoside used. It is also beneficial if the selected alkyl glycoside is metabolized or excreted in the body, and if this metabolism or excretion occurs in a manner that does not exhibit harmful toxicity. As used herein, the term “non-irritating” means that the agent does not cause inflammation after immediate, prolonged, or repeated contact with the skin surface or mucous membranes.
[0066] The compositions disclosed herein are typically present in amounts of about 0.01% to 20% by weight, based on 100% of the composition weight. For example, the compositions may be present in amounts of about 0.01% to 5% by weight, about 0.01% to 2% by weight, about 0.01% to 1% by weight, or about 0.01% to 0.125% by weight, based on 100% of the composition weight. Carbohydrate surfactants can be formulated to be compatible with other components present in the composition. In liquid, gel, capsule, or injectable or spray compositions, carbohydrate surfactants may be formulated to promote the stability of the CGRP inhibitor, or at least prevent its degradation. Furthermore, the compositions are optimized in concentration by keeping the concentration of the absorption enhancer as low as possible while still maintaining the desired effect.
[0067] The compositions disclosed herein, when administered to a subject, enhance the mucosal delivery of CGRP inhibitors and increase the peak concentration (or C) in the subject's tissue, body fluid, or plasma. max ) refers to the C of the compound in tissue (e.g., the central nervous system or CNS), body fluids, or plasma after intramuscular injection of an equivalent concentration of the compound into the subject. max In comparison, these figures are approximately 1.15%, 1.25%, 1.50%, 1.75%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% or more.
[0068] The criterion for how much of a CGRP inhibitor reaches the bloodstream over a set period, e.g., 24 hours, can also be calculated by plotting the drug blood concentration at various time points over a 24-hour or longer period, and then measuring the area under the curve (AUC) between 0 and 24 hours. Similarly, the criterion for drug efficacy can be calculated by the time (T) to reach the maximum concentration of the biologically active compound in the target tissue (e.g., CNS) or body fluid or plasma, between approximately 0.1 and 1.0 hours. max ) can also be determined from. The therapeutic compositions disclosed herein increase the rate of drug action by about 1.5 times or more, for example, about 1.5 to about 5 times, about 1.5 to about 4 times, about 1.5 to about 3 times, or about 1.5 to about 2 times (i.e., T max(Reduce).
[0069] Furthermore, therapeutic compositions or formulations according to embodiments of the present invention can be administered or delivered to subjects requiring systemic or local treatment. Suitable routes include, for example, oral, ocular, nasal, nasal-to-brain, nasal lacrimal, inhalation or lung, oral cavity (sublingual or buccal), transmucosal administration, vaginal, rectal; intramuscular, subcutaneous, intravenous, intraperitoneal, or parenteral delivery, including CSF delivery. In addition, the mode of delivery, such as liquid, gel, tablet, or spray, will depend on the method of delivery to the subject.
[0070] Furthermore, therapeutic compositions according to embodiments of the present invention may include pharmaceutically acceptable carriers. As used herein, the term “pharmaceutically acceptable carrier” means an aqueous or non-aqueous agent, e.g., an alcoholic or oily agent, or a mixture thereof, and may contain surfactants, emollients, lubricants, stabilizers, dyes, fragrances, preservatives, acids or bases for pH adjustment, solvents, emulsifiers, gelling agents, humectants, stabilizers, wetting agents, sustained-release agents, wetting agents, or other components commonly found in certain forms of pharmaceutical compositions. Pharmaceutically acceptable carriers are well known in the art and include, for example, aqueous solutions such as water or physiologically buffered saline, or other solvents or media such as glycols or glycerol, and oils such as olive oil or organic esters for injection. A pharmaceutically acceptable carrier may contain, for example, physiologically acceptable compounds that act to stabilize or increase the absorption of a particular inhibitor, such as carbohydrates like glucose, sucrose, or dextran; antioxidants like ascorbic acid or glutathione; chelating agents; low molecular weight proteins; or other stabilizers or excipients. A pharmaceutically acceptable carrier may also be selected from substances such as distilled water, benzyl alcohol, lactose, starch, talc, magnesium stearate, polyvinylpyrrolidone, alginic acid, colloidal silica, titanium dioxide, and flavoring agents.
[0071] Furthermore, various oxygen atoms within alkyl carbohydrates or alkyl carbohydrate esters can be substituted with sulfur to reduce their sensitivity to hydrolysis by CGRP inhibitors (Defaye, J. and Gelas, J. in Studies in Natural Product Chemistry (edited by Atta-ur-Rahman), Vol. 8, pp. 315-357, Elsevier, Amsterdam, 1991). For example, heteroatoms in a carbohydrate ring may be oxygen or sulfur, or bonds between monocarbohydrate residues in oligocarbohydrates may be oxygen or sulfur (Horton, D. and Wander, JD, "Thio Sugars and Derivatives," The Carbohydrates: Chemistry and Biochemistry, 2nd edition, Vol. IB, (edited by W. Reyman and D. Horton), pp. 799-842, (Academic Press, New York), (1972)). Oligocarbohydrates can have an α (alpha) or β (beta) anomeric configuration (see Pacsu, E. et al., Methods in Carbohydrate Chemistry (eds. RL Whistler et al.), Vol. 2, pp. 376-385, Academic Press, New York 1963).
[0072] Compositions according to embodiments of the present invention can be prepared in tablet form by mixing a CGRP inhibitor, an alkyl glycoside and / or an alkyl carbohydrate ester, and a suitable pharmaceutical carrier or excipient, such as mannitol, corn starch, or polyvinylpyrrolidone; granulating the mixture; and finally compressing it in the presence of a pharmaceutical carrier such as corn starch or magnesium stearate. Optionally, the formulation thus prepared may include a sugar coating or an enteric coating, or may be coated so that the active ingredient is gradually released, for example, in a suitable pH medium.
[0073] The term "enteric coating" refers to a polymer that surrounds, encloses, or forms a layer or film around a therapeutic composition or core. Enteric coatings may also contain CGRP inhibitors that are compatible or incompatible with the coating. For example, a tablet composition may contain an enteric coating polymer with a compatible CGRP inhibitor that dissolves or releases the inhibitor at higher pH levels (e.g., above 4.0, above 4.5, above 5.0, or higher) and does not dissolve or release the inhibitor at lower pH levels (e.g., pH 4 or lower), or vice versa.
[0074] In one embodiment, the dependent-release form of the present invention may be a tablet comprising the following: (a) Cores including the following: (i) CGRP inhibitors; and (ii) Surfactants comprising at least one alkyl glycoside and / or alkyl carbohydrate ester; and (b) at least one film coating surrounding the core, Here, the coating is an impermeable, permeable, semi-permeable, or porous coating that becomes more permeable or porous when in contact with an aqueous environment of a defined pH.
[0075] As used herein, the term “membrane” is synonymous with “coating” or its equivalents. These terms are used to identify areas of a pharmaceutical, such as a tablet, that are impermeable, permeable, semipermeable, or porous to aqueous solutions or body fluids, and / or therapeutic agents or drugs encapsulated therein. If a membrane is permeable, semipermeable, or porous to a CGRP inhibitor, the inhibitor may be released into solution or in vivo through openings or pores in the membrane. Porous membranes may be manufactured mechanically (e.g., by using a laser to create fine holes or pores in the membrane layer) or may be imparted by the physicochemical properties of the coating polymer. The membranes or coating polymers of the present invention are well known in the art and include cellulose esters, cellulose diesters, cellulose triesters, cellulose ethers, cellulose ester-ethers, cellulose acylates, cellulose diacylates, cellulose triacylates, cellulose acetate, cellulose diacetate, cellulose triacetate, cellulose propionate acetate, and cellulose butyrate acetate. Other suitable polymers are described in U.S. Patents No. 3,845,770, No. 3,916,899, No. 4,008,719, and No. 4,036,228.
[0076] Furthermore, the enteric coatings described herein may contain plasticizers and sufficient amounts of sodium hydroxide (NaOH) to achieve or adjust the pH of the suspension in solution or in vivo. Examples of plasticizers include triethyl citrate, triacetin, tributyl sebecate, or polyethylene glycol. Other alkalizing agents, including potassium hydroxide, calcium carbonate, sodium carboxymethylcellulose, magnesium oxide, and magnesium hydroxide, may also be used to achieve or adjust the pH of the suspension in solution or in vivo.
[0077] Therefore, in one embodiment, an enteric coating can be designed to release a specific percentage of a CGRP inhibitor in a specific medium having a specific pH or pH range. For example, a composition according to an embodiment of the present invention may include at least one enteric coating that encapsulates or protects at least one CGRP inhibitor that is chemically unstable in an acidic environment (e.g., the stomach). The enteric coating protects the CGRP inhibitor from an acidic environment (e.g., pH < 3), while releasing the inhibitor in less acidic areas, e.g., the small and large intestines where the pH is 3, 4, 5, or higher. A drug of this nature moves from one area of the gastrointestinal tract to another, but for example, it takes about 2 to 4 hours for a CGRP inhibitor to move from the stomach to the small intestine (duodenum, jejunum, and ileum). During this movement or passage, the pH changes from about 3 (e.g., stomach) or 4 or 5 to about 6 or 7, or higher. Therefore, the enteric coating allows the core containing the CGRP inhibitor to remain substantially intact, preventing premature release of the inhibitor or destabilization by acid penetration.
[0078] Examples of suitable enteric-coated polymers include cellulose phthalate acetate, hydroxypropyl methylcellulose phthalate, polyvinyl phthalate acetate, methacrylic acid copolymer, shellac, cellulose trimetate acetate, hydroxypropyl methylcellulose succinate acetate, hydroxypropyl methylcellulose phthalate, cellulose phthalate acetate, cellulose succinate acetate, cellulose malate acetate, cellulose benzoate phthalate, cellulose propionate phthalate, methylcellulose phthalate, carboxymethyl ethylcellulose, ethyl hydroxyethylcellulose phthalate, shellac, styrene-acrylic acid copolymer, methyl acrylate-acrylic acid copolymer, methyl acrylate-methacrylic acid copolymer, butyl acrylate-styrene-acrylic acid copolymer, methacrylic acid Examples of such copolymers include, but are not limited to, acid-methyl methacrylate copolymers, methacrylate-ethyl acrylate copolymers, methyl acrylate-methacrylate-octyl acrylate copolymers, vinyl acetate-maleic anhydride copolymers, styrene-maleic anhydride copolymers, styrene-maleic acid monoester copolymers, vinyl methyl ether-maleic anhydride copolymers, ethylene-maleic anhydride copolymers, vinyl butyl ether-maleic anhydride copolymers, acrylonitrile-methyl acrylate-maleic anhydride copolymers, butyl acrylate-styrene-maleic anhydride copolymers, polyvinyl alcohol phthalate, polyvinyl acetal phthalate, polyvinyl butyrate phthalate, and polyvinyl acetal phthalate, or combinations thereof. Those skilled in the art will recognize that other hydrophilic, hydrophobic, and enteric coating polymers can be readily used, alone or in any combination, as all or part of the coatings according to embodiments of the present invention.
[0079] The therapeutic compositions of the present invention in tablet form may have multiple coatings, e.g., hydrophilic coatings (e.g., hydroxypropyl methylcellulose) and / or hydrophobic coatings (e.g., alkylcellulose) and / or enteric coatings. For example, the tablet core may be coated with multiple coatings of the same type or multiple different types, selected from hydrophilic, hydrophobic, or enteric coatings. Thus, it is expected that a tablet may have two or more layers consisting of the same or different coatings, depending on the target tissue or purpose of the CGRP inhibitor, but may be designed to have at least one layer. For example, the tablet core layer may have a first composition surrounded by a first coating layer (e.g., hydrophilic, hydrophobic, or enteric coating), and a second same or different composition or CGRP inhibitor having the same or different dose, which may be surrounded by a second coating layer. This layering of various coatings results in first, second, third, or more stepwise or dose-dependent release of the same or different CGRP inhibitor-containing compositions.
[0080] In one embodiment, a first dose of the first composition of the present invention is contained within a tablet core together with an enteric coating, so that the enteric coating protects and prevents the composition contained therein from disintegrating or being released into the stomach. In another embodiment, a first loading dose of the therapeutic composition is contained in a first layer and comprises about 10% to about 40% of the total amount of the entire composition contained in the formulation or tablet. A second loading dose releases another percentage of the total amount of the composition. The present invention intends for a number of release doses desired in a treatment regimen. Thus, in some embodiments, a single coating or multiple coating layers may be in the range of about 2% to about 6% by weight of the coated unit dosage form, for example, about 2% to about 5% by weight, for example, about 2% to about 3% by weight.
[0081] Therefore, formulations according to embodiments of the present invention enable the selective release of the contents of a hard capsule or tablet at a desired site in the more distal part of the gastrointestinal tract (e.g., the small and large intestines) by selecting a pH-soluble polymer suitable for a specific region. Furthermore, mechanical release of the prepared composition can be achieved by including a water-absorbing polymer that swells upon absorbing water within a hard, semi-permeable capsule, thereby extruding the composition from the opening of the hard capsule.
[0082] Furthermore, those skilled in the art will understand that specific dose levels and administration frequencies for any particular subject requiring treatment may vary and will depend on a variety of factors, including the activity of the particular CGRP inhibitor used, the metabolic stability and duration of action of the compound, age, weight, overall health, sex, diet, mode and frequency of administration, elimination rate, drug combinations, severity of the particular condition, and the treatment the host is receiving.
[0083] Alkyl glycosides, such as alkyl maltosides, such as dodecyl maltoside (DDM) and tetradecyl maltoside (TDM), can stabilize CGRP inhibitors in solution and prevent their aggregation. Therefore, one aspect of the present invention provides a therapeutic composition comprising at least one CGRP inhibitor and one carbohydrate surfactant, wherein the surfactant further comprises at least one alkyl glycoside and / or a carbohydrate alkyl ester formulation that enhances the bioavailability of the CGRP inhibitor. The determination of the bioavailability of a drug formulation is described herein. As used herein, “bioavailability” refers to the rate and extent to which an active substance or portion reaches the systemic circulation as an intact drug. The bioavailability of any drug depends on how well it is adsorbed and how much it escapes hepatic removal.
[0084] To determine absolute bioavailability, the test drug and mode of administration are measured relative to an intravenous reference dose. The bioavailability of an intravenous dose is, by definition, 100%. For example, an intravenous injection of the drug and a corresponding oral dose are administered to an animal or human volunteer. Urine or plasma samples are collected over a period of time and the drug levels during that period are determined.
[0085] The area under the curve (AUC) of the plasma drug concentration-time curve is plotted for both the intravenous and oral doses, and the bioavailability of both formulations is calculated proportionally. For example, if the same intravenous and oral doses are administered and the oral AUC is 50% of the intravenous AUC, the bioavailability of the oral formulation is 50%. In fact, the bioavailability of any drug is due to many factors, including incomplete absorption, first-pass clearance, or combinations of these (discussed in more detail below). Further, the peak concentration (or C max ) of the drug in plasma is also measured and compared to the peak concentration (C max ) of the drug in plasma after intramuscular (IM) injection of an equivalent concentration of the drug. Further, the time to reach the maximum concentration (or T max ) of the drug in plasma is about 0.1 - 1.0 hours.
[0086] To determine the relative bioavailability of two or more formulations of a drug (e.g., drug formulations of alkyl glycosides or carbohydrate alkyl esters), the bioavailability of the formulations is evaluated relative to each other because one or both drugs may undergo first-pass clearance (discussed in more detail below), which may thereby not be detected. For example, a first oral formulation is evaluated relative to a second oral formulation. The second formulation is used as a reference for evaluating the bioavailability of the first formulation. This type of study provides a measure of the relative performance of two formulations when the drug is absorbed.
[0087] The alkyl glycosides or carbohydrates according to embodiments of the present invention include any currently known or subsequently discovered compounds. CGRP inhibitors particularly suitable for miscibility with alkyl glycosides and / or alkyl carbohydrate esters are those that are difficult to administer by other means, such as compounds that are degraded in the gastrointestinal (GI) tract or not adequately absorbed from the GI tract, or compounds that can be self-administered orally, orally, nasally, nasally, by inhalation, sublingually, or via CSF delivery routes, instead of conventional methods such as injection.
[0088] Alternatively, the bioavailability of CGRP inhibitors can be determined by measuring the level of first-pass clearance of the drug by the liver. The alkyl glycoside and / or carbohydrate alkyl ester compositions of the present invention, administered intranasally or orally (sublingual or buccal), do not enter the hepatic portal system and thereby evade first-pass clearance by the liver. Evading first-pass clearance of these formulations by the liver is described herein. As used herein, the term “first-pass hepatic clearance” is the extent to which a drug is removed by the liver during its first pass from the portal blood through the liver to the systemic circulation. This is also called first-pass metabolism or first-pass extraction.
[0089] The two main pathways by which drugs are excreted from the body are renal excretion, in which the drug remains unchanged, and hepatic excretion, in which the drug is metabolized. The balance between these two pathways depends on the relative efficiency of these two processes. This invention describes excretion by hepatic clearance in this specification. First-pass hepatic clearance was described by Birkett et al. (1990 and 1991), which is incorporated in its entirety by reference. Birkett et al., Aust Prescr, 13(1990):88~9; and Birkett et al., Aust Prescr, 14:14~16(1991).
[0090] Blood carrying a drug from the systemic circulation enters the liver via the portal vein, where the liver extracts a certain percentage or ratio (i.e., 0.5 or 50%) of the drug. The remaining residue (i.e., 0.2 or 20%) re-enters the systemic circulation via the hepatic vein. This clearance rate of a drug is called the hepatic extraction ratio. It is the percentage of the drug in the blood that is irreversibly removed (or extracted) during the initial pass of the blood through the liver. If no drug is extracted, the hepatic extraction ratio is zero. Conversely, if a very large amount of the drug is extracted during the first pass through the liver, the hepatic extraction ratio can be as high as 100% or 1.0. In general, the clearance of a drug by the liver depends, in that case, on the rate of delivery (or hepatic blood flow) of the drug to the liver and the efficiency (or extraction ratio) of its removal.
[0091] Therefore, the final formula used to determine liver clearance is as follows: (Hepatic clearance - blood flow) = (unbound rate * intrinsic clearance) / blood flow + (unbound rate * intrinsic clearance) (1)
[0092] The "unbound rate" of a drug depends on how strongly it binds to proteins and cells in the blood. Generally, only this unbound (or free) drug is available for diffusion from the blood to hepatocytes. In the absence of hepatic blood flow and protein binding, "intrinsic clearance" is the liver's ability to remove (or metabolize) the drug. In biochemical terms, this is an indicator of hepatic enzyme activity for a particular drug substrate. Also, even if intrinsic clearance can be high, the drug may not be removed as quickly as it was delivered to the liver. Simply put, there are two situations: hepatic enzyme activity is very high or very low (i.e., high or low extraction ratio).
[0093] If liver enzyme activity is low, the formula can be simplified as follows: Liver clearance = non-binding rate * intrinsic clearance (2)
[0094] In this case, clearance does not depend on blood flow, but rather directly on the degree of protein binding in the blood and the activity of drug-metabolizing enzymes for that drug.
[0095] In contrast, when liver enzyme activity is high, the formula is as follows: Liver clearance = hepatic blood flow (3)
[0096] In this view, because the enzyme is highly active, the liver removes most of the drug delivered to it, resulting in a high extraction ratio. Therefore, the only factor determining actual hepatic clearance is the rate of drug delivery (or hepatic blood flow) to the liver.
[0097] First-pass hepatic clearance is important because even small changes in drug extraction can lead to significant changes in bioavailability. For example, if the bioavailability of drug A to reach systemic circulation is 20% when administered orally, and 100% when administered intravenously, then, assuming no other complex factors are present, the oral dose would need to be five times the intravenous dose to achieve a similar plasma concentration.
[0098] Secondly, in some cases where hepatic enzyme activity is very high, drug formulations should be designed so that the drug passes directly into the systemic circulation, completely bypassing first-pass hepatic clearance. For example, drugs administered intranasally, sublingually, buccally, rectally, or vaginally enter the systemic circulation directly and do not enter the hepatic portal blood circulation, which is partially or completely extracted by the liver. Alternatively, if the drug cannot be administered by the above means, a tablet is provided having at least one enteric coating layer to prevent drug release in the stomach (i.e., a highly acidic environment). Thus, one object of the present invention is to administer drugs using these alternative routes.
[0099] Furthermore, since many patients receive two or more drug regimens, which can lead to drug interactions that increase or decrease hepatic enzyme activity, thereby increasing or decreasing the metabolism of the drugs in question (increasing or decreasing the hepatic extraction ratio), first-pass hepatic clearance is an important factor.
[0100] Therefore, the therapeutic compositions of the present invention can be administered directly to the systemic circulation, bypassing first-pass hepatic clearance. By bypassing first-pass clearance, it is ensured that more of the drug becomes available to the system. In other words, bypassing first-pass hepatic clearance increases the bioavailability of the drug.
[0101] Embodiments of the present invention also relate to a method for increasing the absorption of a low molecular weight CGRP inhibitor into a target circulatory system, comprising administering the compound and a suitable non-toxic, non-ionic alkyl glycoside having a hydrophobic alkyl linked to a hydrophilic carbohydrate by binding, in an amount that increases absorption, via oral, ocular, nasal, nasal tear, inhalation, or CSF delivery pathway.
[0102] The formulation of the composition is appropriately selected according to the route of administration, such as oral administration (oral preparation), external administration (e.g., ointment), injection (injectable preparation), and mucosal administration (e.g., cheek and suppository). For example, excipients (e.g., starch, lactose, crystalline cellulose, calcium lactate, magnesium aluminometasilicate, and anhydrous silicic acid), disintegrants (e.g., carboxymethylcellulose and carboxymethylcellulose calcium), lubricants (e.g., magnesium stearate and talc), coating agents (e.g., hydroxyethylcellulose), and flavoring agents may be used in oral and mucosal preparations; on the other hand, solubilizers and auxiliary solubilizers that can form aqueous injectable preparations (e.g., distilled water for injection, physiological saline, and propylene glycol), suspending agents (e.g., surfactants such as polysorbate 80), pH adjusters (e.g., organic acids and their metal salts), and stabilizers may be used in injectable preparations; and aqueous or oily solubilizers and auxiliary solubilizers (e.g., alcohols and fatty acid esters), tackifiers (e.g., carboxyvinyl polymers and polycarbohydrates), and emulsifiers (e.g., surfactants) may be used in topical preparations. CGRP inhibitors and alkyl glycosides can be mixed, blended, or combined with the above-mentioned excipients, disintegrants, coating polymers, solubilizers, suspending agents, etc., before administration, or they can be administered sequentially in any order. It is preferable to mix them before administration.
[0103] As used herein, the term “mucosal delivery enhancer” includes agents that enhance the release or solubility (e.g., from the formulation delivery medium), diffusion rate, permeation capacity and timing, uptake, residence time, stability, effective half-life, peak or sustained concentration level, clearance, and other desired mucosal delivery properties (e.g., measured at a delivery site such as blood flow or the central nervous system, or a selected active target site) of a compound (e.g., a biologically active compound). Enhancement of mucosal delivery may occur by any variety of mechanisms, for example, by increasing the diffusion, transport, persistence, or stability of a compound; increasing membrane fluidity; modulating the availability or action of calcium and other ions that regulate intracellular or paracellular permeability; solubilizing mucosal components (e.g., lipids); altering sulfhydryl levels of non-proteins and proteins in mucosal tissue; increasing water flow across the mucosal surface; modulating epithelial junctional physiological function; reducing the viscosity of mucus covering the mucosal epithelium; reducing the mucociliary clearance rate; and other mechanisms.
[0104] Examples of mucosal delivery enhancers include the following drugs and any combination thereof: ○ (a) Aggregation inhibitors; ○ (b) Charge modifiers; ○ (c) pH adjuster; ○ (d) Degrading enzyme inhibitors; ○ (e) Mucus dissolving agents or mucus removers; ○ (f) Ciliary quiescent agent; ○ (g) Membrane permeability enhancers selected from the following: (i) Surfactants; (ii) Bile salts; (ii) Phospholipid additives, mixed micelles, liposomes, or carriers; (iii) Alcohols; (iv) Enamines; (v) NO donor compounds; (vi) Long-chain amphiphilic molecules; (vii) Small hydrophobic permeability enhancers; (viii) Sodium or salicylic acid derivatives; (ix) Glycerol esters of acetoacetate; (x) Cyclodextrin or beta-cyclodextrin derivatives; (xi) Medium-chain fatty acids; (xii) Chelating agents; (xiii) Amino acids or their salts; (xiv) N-acetylamino acids or their salts; (xv) Enzymes that degrade selected membrane components; (ix) Inhibitors of fatty acid synthesis; (x) Inhibitors of cholesterol synthesis; and (xi) Any combination of membrane permeability enhancers listed in (i) to (x); ○ (h) Regulators of epithelial junctional physiological function; ○ (i) Vasodilators; ○ (j) Selective transport enhancers; and ○ (k) A stabilizing delivery medium, carrier, mucosal adhesive, support, or complex-forming species that is effectively combined with, associated with, contained in, encapsulated in, or bound to a compound, resulting in stabilization of the compound for enhanced nasal mucosal delivery, the formulation of the compound with the intranasal delivery enhancer resulting in increased bioavailability of the compound in the target plasma.
[0105] Additional mucosal delivery enhancers include, for example, citric acid, sodium citrate, propylene glycol, glycerin, ascorbic acid (e.g., L-ascorbic acid), sodium metabisulfite, disodium ethylenediaminetetraacetic acid (EDTA), benzalkonium chloride, sodium hydroxide, and mixtures thereof. For example, EDTA or its salts (e.g., sodium or potassium) are used in amounts ranging from about 0.01% to 2% by weight of the composition containing the alkyl carbohydrate preservative.
[0106] Compounds whose absorption can be increased by the methods described herein include any currently known or subsequently discovered CGRP inhibitors, in particular compounds that are difficult to administer by other means, such as compounds that are broken down in the gastrointestinal (GI) tract or compounds that are not adequately absorbed from the GI tract, or compounds that can be administered by the subject more easily than traditional self-administration methods such as injection, via oral, ocular, nasal, nasal-to-brain, nasal tears, inhalation or lung, oral cavity (sublingual or buccal cells), or CSF delivery routes.
[0107] As discussed herein, varying amounts of CGRP inhibitors may be absorbed as they pass through the cheek, sublingual, oropharyngeal, and preesophageal portions of the gastrointestinal tract. However, the majority of CGRP inhibitors enter the stomach and are absorbed in the usual manner, as enteric-coated dosage forms such as tablets, capsules, or liquids are absorbed. Once absorbed from the intestines, compounds are transported directly to the liver, where, depending on their specific chemical structure, they may be metabolized and excreted by enzymes that carry out the normal detoxification process in hepatocytes. This excretion is called “first-pass” metabolism or the “first-pass” effect in the liver, as discussed earlier. The resulting metabolites are, in most cases, substantially or completely inactive compared to the original molecule and often circulate in the bloodstream before being excreted in urine and / or feces.
[0108] Aspects of the present invention are based on the finding that the addition of certain alkyl carbohydrates, when included in a rapidly dispersible dosage form, modulates the proportion of CGRP inhibitors that undergo the first-pass effect, and thus allows a certain amount of CGRP inhibitor to exert greater clinical utility, or a smaller amount of CGRP inhibitor to achieve similar clinical utility compared to different, larger doses.
[0109] Accordingly, in one aspect of the present invention, the pharmaceutical composition is prepared in a solid-molded, orally rapidly dispersible dosage form, as described in U.S. Patent No. 9,192,580 issued November 24, 2015.
[0110] As used herein, the term “rapidly dispersible dosage form” refers to a composition that disintegrates or disperses within 1 to 60 seconds, for example, 1 to 50 seconds, 1 to 40 seconds, 1 to 30 seconds, 1 to 20 seconds, 1 to 10 seconds, or 2 to 8 seconds, after contact with a body fluid. The body fluid is preferably what is found in the oral cavity, i.e., saliva, as in the case of oral administration.
[0111] In one embodiment, the composition described herein is a solid rapidly dispersible dosage form comprising an active ingredient, for example, a solid network of zabegepant, and a water-soluble or water-dispersible carrier containing fish gelatin. The carrier is therefore inert to the active ingredient. The network is obtained by sublimating a solvent from a solid composition, and this composition comprises the active ingredient and a solution containing the carrier in a solvent. The dosage form according to the present invention can be prepared according to the method disclosed in Gregory et al., UK Patent No. 1,548,022, using fish gelatin as the carrier. Thus, an initial composition (or admixture) is prepared comprising the active ingredient and a solution containing a fish gelatin carrier in a solvent, followed by sublimation. Sublimation is preferably carried out by freeze-drying the composition. The composition can be placed in a mold during the freeze-drying process to produce a solid form of any desired shape. The mold can be cooled in a preliminary step using liquid nitrogen or solid carbon dioxide before depositing the composition therein. After freezing the mold and composition, they are then reduced in pressure and, if necessary, heated under controlled conditions to aid in the sublimation of the solvent. The reduced pressure applied during the process may be less than approximately 4 mmHg, preferably less than approximately 0.3 mmHg. The freeze-dried composition can then be removed from the mold as desired, or stored in it until later use.
[0112] Using a process with fish gelatin as the active ingredient and carrier produces a solid, rapidly dispersible dosage form having the advantages associated with the use of fish gelatin as described herein. Generally, fish gelatin is classified as originating from cold-water and warm-water fish, and as gelling or non-gelling types. Non-gelling types of fish gelatin have lower content of proline and hydroxyproline amino acids, which are known to be associated with crosslinking properties and gelling ability, compared to gelling fish gelatin and bovine gelatin. Non-gelling fish gelatin can survive at solution concentrations of up to about 40% and at low temperatures of 20°C. In one aspect of the present invention, the fish gelatin used according to the present invention is preferably a non-gelling type fish gelatin obtained from a cold-water fish source. More preferably, in one aspect of the present invention, non-hydrolyzable non-gelling fish gelatin is used. In alternative embodiments, spray-dried non-hydrolyzable non-gelling fish gelatin can be used. Fish gelatin suitable for use in the compositions described herein is commercially available.
[0113] The compositions according to embodiments of the present invention may also include other matrix-forming agents and secondary components in addition to the active ingredient and fish gelatin carrier. Suitable matrix-forming agents include other gelatins, dextrins, and materials derived from animal or plant proteins such as soy, wheat, and psyllium seed proteins; gums such as acacia, guar, agar, and xanthan gum; polycarbohydrates; alginates; carboxymethylcellulose; carrageenan; dextran; pectin; synthetic polymers such as polyvinylpyrrolidone; and polypeptide / protein or polycarbohydrate complexes such as gelatin-acacia complexes.
[0114] Other materials that can be incorporated into the rapidly soluble compositions according to embodiments of the present invention include sugars such as mannitol, dextrose, lactose, galactose, and trehalose; cyclic sugars such as cyclodextrin; inorganic salts such as sodium phosphate, sodium chloride, and aluminum silicate; and amino acids having 2 to 12 carbon atoms such as glycine, L-alanine, L-aspartic acid, L-glutamic acid, L-hydroxyproline, L-isoleucine, L-leucine, and L-phenylalanine. One or more matrix-forming agents can be incorporated into the solution or suspension before solidification (freezing). The matrix-forming agents can be present in addition to or without surfactants. In addition to forming a matrix, the matrix-forming agents can help maintain the dispersion of any active ingredients in the solution of the suspension. This is particularly useful in the case of surfactants that must be suspended rather than dissolved because they do not dissolve well in water. Secondary components such as preservatives, antioxidants, surfactants, viscosity enhancers, colorants, flavorings, pH adjusters, sweeteners, or flavor masking agents can also be incorporated into the fast-dissolving composition. Suitable colorants include red, black, and yellow iron oxides, as well as FD&C dyes such as FD&C Blue No. 2 and FD&C Red No. 40, available from Ellis & Everard. Suitable flavorings include mint, raspberry, licorice, orange, lemon, grapefruit, caramel, vanilla, cherry, and grape flavorings, as well as combinations thereof. Suitable pH adjusters include edible acids and bases such as citric acid, tartaric acid, phosphoric acid, hydrochloric acid, maleic acid, and sodium hydroxide. Suitable sweeteners include, for example, sucralose, aspartame, acesulfamethoxazole K, and thaumatin. Suitable flavor masking agents include, for example, sodium bicarbonate, ion exchange resins, cyclodextrin inclusion compounds, adsorbents, or microencapsulated active ingredients.
[0115] Increasing or decreasing the amount of specific alkyl carbohydrates in a rapidly dispersing dosage form can alter or modulate the absorption site of CGRP inhibitors, thereby increasing or decreasing the proportion of CGRP inhibitors absorbed through the buccal tissue compared to other parts of the gastrointestinal tract. This accelerates the onset of drug action, but also reduces the longer-than-usual time signature associated with standard oral tablets. max If it is desirable to maintain the buccal absorption, reducing the alkyl glycoside content will attenuate buccal absorption, resulting in some of the drug being absorbed quickly through the buccal, while the remainder is absorbed through a slower gastric absorption process. While not strictly theoretical, it will be understood that, if clinically desirable, a broader absorption peak overall can be achieved in the "systemic drug levels" versus time graph by selecting an alkyl glycoside concentration lower than the alkyl carbohydrate concentration that has been experimentally shown to produce maximum or near-maximum buccal absorption, for example, by selecting a concentration 20% lower.
[0116] Furthermore, in other aspects of the present invention, the pharmacokinetics of gastric drug absorption can be altered in a beneficial manner by adding certain alkyl glycosides having a specific alkyl chain length to rapidly dispersible tablets. For example, the pharmacokinetics of gastric drug absorption can be altered in a beneficial manner by incorporating alkyl glycosides in amounts of approximately 0.2% to 0.3%, 0.3% to 0.4%, 0.4% to 0.5%, 0.5% to 1.0%, 1.0% to 2.0%, 2.0% to 3.0%, 3.0% to 4.0%, 4.0% to 5.0%, 5.0% to 6.0%, 6.0% to 7.0%, 7.0% to 8.0%, 9.0% to 10.0%, and more than 10%. In exemplary embodiments, the alkyl glycoside is dodecylmaltoside, tetradecylmaltoside, and / or sucrose dodecanoate, and incorporating this into a rapidly dispersible tablet format increases the amount of drug entering the systemic circulation and decreases the amount of drug excreted by the "first-pass" effect in the liver. Furthermore, the time to reach maximum drug levels can be dramatically reduced, for example, from 1-6 hours to approximately 15-45 minutes. When used in the treatment of patients with acute migraine symptoms, this more rapid absorption of CGRP inhibitors may result in a faster onset of action and potentially significant benefits.
[0117] Furthermore, in other embodiments of the present invention, when a certain type of rapidly dissolving or rapidly dispersible tablet is placed between the cheek and gums, or in close association with the cheek tissue in the mouth, a larger proportion of the CGRP inhibitor is absorbed directly into the systemic circulation, after which a small amount undergoes first-pass excretion in the liver. Particularly preferred locations for this effect in the mouth are considered to be the inner part of the central portion of the upper lip, between the inner lip and gums, and just below the nose. In exemplary embodiments, these types of rapidly dissolving formulations are prepared by lyophilization or vacuum drying. In one exemplary embodiment, the formulation is prepared in a manner that results in a substantially porous formulation.
[0118] As used herein, the term “rapidly dispersible dosage form” is intended to encompass all types of dosage forms that can be completely or partially dissolved in the mouth. However, in exemplary embodiments, a rapidly dispersible dosage form is a rapidly dispersible solid network of an active ingredient and a water-soluble or water-dispersible carrier matrix that is inert to the active ingredient and excipients. As described above, the network can be obtained by lyophilizing or sublimating a solvent from a solid-state composition comprising the active ingredient, an alkyl glycoside, and a solution containing the carrier in the solvent. A variety of solvents suitable for this use are known in the art, but one solvent particularly suitable for use in the present invention is water. Water-alcohol mixtures can also be used if the solubility of the CGRP inhibitor in the mixed solvent is to be increased. In the case of poorly water-soluble drugs, dispersions of small drug particles can be suspended in an aqueous gel that maintains a uniform distribution of substantially insoluble drugs during the lyophilization or sublimation process.
[0119] In one embodiment, the dosage form may contain a CGRP antagonist in an amount of about 10-80% by weight, for example, about 20-80%, about 30-80%, about 40-80%, or about 50-80% by weight, relative to the total weight of the dosage form. The dosage form may further contain an alkyl glycoside in an amount of about 0.01-50% by weight, for example, about 0.1-50%, about 1-50%, about 5-50%, or about 10-50% by weight, relative to the total weight of the dosage form. The dosage form may further contain fish gelatin in an amount of about 10-30% by weight, for example, about 15-30% or about 20-30% by weight, relative to the total weight of the dosage form. The dosage form may further contain a filler in an amount of about 10-25% by weight.
[0120] In one embodiment, the aqueous gel may be a self-assembling hydrogel as described in U.S. Patent Application No. 60 / 957,960, formed using mono-sucrose distearate and / or selected alkyl glycosides such as tetradecyl maltoside.
[0121] Matrix-forming agents suitable for use in the rapidly soluble formulations of the present invention are described throughout this application. Such agents include materials derived from animal or plant proteins such as gelatin, collagen, dextrin, and soy, wheat, and psyllium seed proteins; gums such as acacia, guar, agar, and xanthan gum; polycarbohydrates; alginates; carrageenan; dextran; carboxymethylcellulose; pectin; synthetic polymers such as polyvinylpyrrolidone; and polypeptide / protein or polycarbohydrate complexes such as gelatin-acacia complexes. In exemplary embodiments, gelatin, particularly fish gelatin or porcine gelatin, is used.
[0122] While virtually any CGRP antagonist can be incorporated into the rapidly soluble formulations described herein, particularly suitable CGRP antagonists are those with low oral bioavailability (e.g., less than 80%), such as BHV-3500.
[0123] Zabegepant ODT preparation In one embodiment, the pharmaceutical composition may comprise a pharmaceutically acceptable carrier and a therapeutically effective amount of zavegepant, its solvate, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition is in the form of a solid-molded orally rapidly dispersible dosage form. Such a pharmaceutical composition may be formulated, for example, as an orally disintegrating tablet (ODT). A solid-molded orally rapidly dispersible dosage form of a CGRP inhibitor is described, for example, in international application PCT / US2019 / 023940, filed on 25 March 2019 and published on 3 October 2019 as WO2019 / 191008A1, which is incorporated herein by reference in its entirety.
[0124] Soft gel formulation of CGRP inhibitor In one embodiment, the soft gel pharmaceutical formulation may include the following: A synthetic or naturally occurring poorly permeable calcitonin gene-related peptide (CGRP) inhibitor or its salt or solvate in an amount of 0.01 to 20% by weight of the total weight of the preparation; A lipophilic phase containing fatty acid triglycerides in an amount of 50-80% by weight of the total weight of the formulation; and A lipophilic surfactant comprising a partial ester of a polyol and a fatty acid in an amount of 10 to 50% by weight of the total weight of the formulation, at least one such surfactant.
[0125] The above formulations are described, for example, in international application PCT / US2020 / 027800, filed on April 10, 2020, and published on October 15, 2020, as WO2020 / 210722A1, which is incorporated herein by reference in its entirety.
[0126] Treatment method One embodiment provides a method for treating or preventing a condition associated with abnormal levels of CGRP in a subject requiring such treatment, the method comprising administering one of the above-mentioned pharmaceutical compositions and formulations to the subject.
[0127] CGRP inhibitors may be CGRP antibodies, CGRP receptor antibodies, antigen-binding fragments from CGRP antibodies or CGRP receptor antibodies, CGRP injection inhibitor proteins, CGRP reactivators, small molecule CGRP receptor antagonists, small molecule CGRP inhibitors, or polypeptide CGRP inhibitors. Small molecule CGRP receptor antagonists are zabegepant, rimegepant, ubrogepant, atogepant, terkagepant, or orsegepant, their solvates, or pharmaceutically acceptable salts thereof.
[0128] In one embodiment, the condition may be a disorder selected from acute migraine, chronic migraine, cluster headache, chronic tension-type headache, medication overuse headache, post-traumatic headache, post-concussion syndrome, traumatic brain injury, and dizziness.
[0129] In another embodiment, the condition may be a disorder selected from chronic pain, neurogenic vasodilation, neurogenic inflammation, inflammatory pain, neuropathic pain, diabetic peripheral neuropathy, microfibroneuropathy, Morton's neuroma, chronic knee pain, chronic back pain, chronic hip pain, chronic finger pain, exercise-induced myalgia, cancer pain, chronic inflammatory skin pain, burn pain, scar pain, complex regional pain syndrome, oral burning syndrome, alcoholic polyneuropathy, chronic inflammatory demyelinating polyradiculopathy, human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related neuropathy, drug-induced neuropathy, occupational neuropathy, lymphomatous neuropathy, myelomatous neuropathy, multifocal motor neuropathy, chronic idiopathic sensory neuropathy, cancerous neuropathy, acute pain autonomic neuropathy, compressive neuropathy, vasculitic / ischemic neuropathy, temporomandibular joint pain, postherpetic neuralgia, trigeminal neuralgia, chronic regional pain syndrome, eye pain, and toothache.
[0130] For example, the condition may be medication overuse headache (MOH), and a person with this condition may receive treatment for pain, which may include medications selected from acute and chronic pain medications. For example, treatment for pain may include medications selected from triptans, ergot alkaloids, analgesics, and opioids. Triptans may be selected from rizatriptan, sumatriptan, naratriptan, eletriptan, donitriptan, alumotriptan, flovatriptan, abitriptan, and zolmitriptan. Ergot alkaloids may be selected from cravin, lysergic acid amide, and ergopeptine. Ergot alkaloids may also be selected from ergonovine, methylergonovine, methyserzide, ergotamine, dihydroergotamine, bromocriptine, ergoloid mesylate, and diethylamide lysergic acid, or combinations thereof.
[0131] MOH may result from the chronic use of one or more analgesics. Participants may have a primary headache disorder selected from migraine, cluster headache, or tension headache. Participants may be currently receiving treatment or have previously received treatment for a primary headache disorder.
[0132] For pain management, medications selected from aspirin, diclofenac; diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketrolac, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sarsalate, sulindac, tolmetin, celecoxib, rofecoxib, etoricoxib, valdecoxib, parecoxib, meloxicam, lumiracoxib, or combinations thereof may be used.
[0133] MOH may result from treatment with a selection of pharmaceuticals from the following: ketamine, esketamine, alfentanil, alimazine, alprazolam, amphetamine, buprenorphine, butorphanol, clonazepam, codeine, cyclobenzaprine, diazepam, dihydrocodeine, dihydromorphine, dronabinol, estazolam, ezopiclone, fentanyl, flurazepam, hydrocodone, hydromorphone, lorazepam, metbarbital, methylphenidate, methadone, morphine, oxycodone, oxymorphone, phenobarbital, secobarbital, tenpazepam, tramadol, triazolam, zaleplon, zopiclone, and zolpidem.
[0134] MOH may result from chronic use of a selection of medications including alimazine, alprazolam, amphetamine, buprenorphine, butorphanol, clonazepam, codeine, cyclobenzaprine, diazepam, dihydrocodeine, dihydromorphine, dronabinol, estazolam, ezopiclone, fentanyl, flurazepam, hydrocodone, hydromorphone, lorazepam, metbarbital, methylphenidate, methadone, morphine, oxycodone, oxymorphone, phenobarbital, secobarbital, tenpazepam, tramadol, triazolam, zaleplon, zopiclone, and zolpidem.
[0135] MOH includes aspirin, ibuprofen, naproxen, acetaminophen, diclofenac, flurbiprofen, meclofenamate, isometeptene, indomethacin; codeine, morphine, hydrocodone, acetyldihydrocodeine, oxycodone, oxymorphone, papaverine, fentanyl, alfentanil, sufentanil, remifentanil, tramadol, prochlorperazine, celecoxib, rofecoxib, meloxicam, piroxicam, JTE-522, L-745, 337, NS388, delacoxib, valdecoxib, imiracoxib, etoricoxib, parecoxib, 4-(4-cyclohexyl-2- Methyloxazol-5-yl)-2-fluorobenzenesulfonamide, (2-(3,5-difluorophenyl)-3-(4-(methylsulfonyl)phenyl)-2-cyclopenten-l-one, N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)pyridazinone, 2-[(2,4-dichloro-6-methylphenyl)amino]-5-ethylbenzeneacetic acid, (3Z)3-[(4-chlorophenyl)[4-(methylsulfonyl)phenyl]methylene]dihydro-2(3H)-furanone, (S)-6,8-Dichloro-2-(trifluoromethyl)-2H-l-benzopyran-3-carboxylic acid, amobarbital, butalbital, cyclobarbital, pentobarbital, allobarbital, methylphenobarbital, phenobarbital, secobarbital, vinylbital, verapamil, siltiazem, nifedipine, lidocaine, tetracaine, prilocaine, bupivicaine, mepivacaine, etidocaine Procaine, benzocaine, phehelzine, isocarboxazide, dichlorphenazone, nimopidin, metoclopramide, capsaicin receptor agonists, captopril, thiospirone, steroids, caffeine, metoclopramide, domperidone, scopolamine, dimenhydrinate, diphenhydramine, hydroxyzine, diazepam, lorazepam, chlorpromazine, metotrimeprazine, perphenazine, Chronic use of pharmaceuticals selected from prochlorperazine, promethazine, trifluoperazine, triflupromazine, benzquinamide, bismuth subsalicylate, buclidine, cinnarizine, cyclizine, diphenidol, drasetron, domperidone, dronabinol, droperidol, haloperidol, metoclopramide, nabilone, thiethylperazine, trimethobenzemide, and eziopitant, meclizine, domperidone, ondansetron, tropisetron, granisetron, drasetron, hydrodrasetron, palonosetron, alosetron, silancetron, cisapride, lenzaprid, metoclopramide, galanolactone, phencyclizine, ketamine, dextromethorphan, and their isomers, pharmaceutically acceptable salts, esters, complexes, or prodrugs may be derived from the chronic use of these drugs.
[0136] In another example, the condition may be post-traumatic headache (PTH), and subjects with this condition may experience PTH one, two, three, four, five, six, or seven days after the traumatic incident. The traumatic incident may result in a concussion or loss of consciousness. Subjects may suffer from dizziness, insomnia, difficulty concentrating, memory impairment, photophobia, phonophobia, or fatigue, or a combination thereof.
[0137] In another embodiment, the conditions include: non-insulin-dependent diabetes mellitus, vascular disorders, inflammation, arthritis, burns, circulatory shock, sepsis, alcohol withdrawal syndrome, opioid withdrawal syndrome, morphine tolerance, hot flashes in men and women, menopausal flashes, allergic dermatitis, psoriasis, encephalitis, ischemia, stroke, epilepsy, neuroinflammatory disorders, neurodegenerative diseases, skin diseases, neurogenic erythema, skin rosaceousness, erythema, tinnitus, obesity, inflammatory bowel disease, irritable bowel syndrome, vulvodynia, polycystic ovary syndrome, uterine fibroids, neurofibromatosis, hepatic fibrosis, renal fibrosis, focal segmental glomerulosclerosis, glomerulonephritis, IgA nephropathy, multiple myeloma, myasthenia gravis, Sjögren's syndrome, osteoarthritis, and osteoarthritis-induced degenerative disc disease. The disorder may be selected from temporomandibular joint disorder, whiplash injury, rheumatoid arthritis, and interstitial cystitis. The method according to claim 61, wherein the skin disorder is selected from recurrent herpes, contact hypersensitivity, nodular prurigo, chronic pruritus, and uremic pruritus.
[0138] In another embodiment, the condition may be a disorder selected from chronic obstructive pulmonary disease, pulmonary fibrosis, bronchial hypersensitivity, asthma, cystic fibrosis, chronic idiopathic cough, and toxic injury. Toxic injury is selected from chlorine gas injury, mustard gas injury, acrolein injury, smoke injury, ozone injury, military chemical exposure, and industrial chemical exposure.
[0139] The present invention is described in more detail in the following embodiments, which are intended for illustrative purposes only, as numerous modifications and variations will be apparent to those skilled in the art. The following embodiments are illustrative and not limiting to the present invention. [Examples]
[0140] (Example 1) In this example, the pharmacokinetics (PK) of BHV-3500 after a single sublingual (tablet) administration in dogs were investigated, and the PK parameters were determined.
[0141] BHV-3500 (zabegepant) is a highly affinity (human CGRP Ki=0.023nM), selective, and structurally unique small molecule CGRP receptor antagonist, and has the following formula I.
[0142] [ka]
[0143] The chemical name of BHV-3500 is (R)-N-(3-(7-methyl-1H-indazole-5-yl)-1-(4-(1-methylpiperidine-4-yl)piperazine-1-yl)-1-oxopropane-2-yl)-4-(2-oxo-1,2-dihydroquinoline-3-yl)piperidine-1-carboxamide. BHV-3500 is described, for example, in WO03 / 104236 published on 18 December 2003 and U.S. Patent No. 8,481,546 issued on 9 July 2013, which are incorporated herein by reference in their entirety. BHV-3500 was selected for the purpose of this study due to its low permeability. BHV-3500-d8 is an octetated analog of BHV-3500 and has the following formula II.
[0144] [ka]
[0145] Explanation of the research protocol
[0146] Research Title: A single-dose sublingual PK study of BHV-3500 in dogs.
[0147] Research objective: To determine the pharmacokinetics of BHV-3500 tablet formulation after a single sublingual administration in dogs.
[0148] Research period: 3 weeks.
[0149] Formula of the test product: Identification. Identify the test sample as BHV-3500. Supply the test sample as tablets. Hazards to workers. Ensure the health and safety of workers handling test samples in accordance with standard safety procedures used for handling hazardous or potentially hazardous chemicals. Characterization of the test specimen. Provide a certificate of analysis (or other appropriate document) that proves the identity or purity of the test specimen. Dosage preparation and analysis. Analysis of the administered formulation will not be performed. Storage. Store BHV-3500 tablets at room temperature. Disposal and retention of samples. Record all quantities of prepared test material. Retention samples are not required for this period of study. Rationale for selecting the test dose. The test dose level was selected based on past PK studies using the test product. Route of administration: The test product will be administered sublingually. Disposal of test samples. After the research is completed, any remaining test samples will be returned and disposed of.
[0150] Experimental design: See Table 1 below.
[0151] Examination System: Test animals. Three female beagle dogs were obtained from Ridglan Farms, Mount Horeb, WI for use in this study. All animals were immunized by the supplier against distemper, adenovirus type 2, parainfluenza, Bordetella, rabies, papillomavirus, and parvovirus. The dogs were approximately one year old and weighed approximately 8-12 kg at the start of administration. The same three animals were used for all test samples. Justification. Dogs are a standard species used in non-clinical toxicity studies and are approved by the U.S. Food and Drug Administration as a large animal (non-rodent) model system for evaluating the safety of pharmacokinetics of pharmaceuticals. Justification for the number of animals used. The number of animals used is the minimum necessary to obtain meaningful data. To the best of the knowledge of the sponsor and principal investigator, conducting this study will not unnecessarily duplicate existing data regarding species, test samples, dosage, administration route, and duration of administration. Living environment. Dogs are housed individually in cages equipped with an automatic watering system. Cages are cleaned daily. Dogs are housed in accordance with the standards set forth in the U.S. Department of Agriculture Welfare Standards (Title 9, Federal Regulatory Code, Part 3, amended 1991) and the Guidelines for the Care and Use of Laboratory Animals (National Research Council, 2011). Feed. Certified Canine Diet #2021C (Harlan Teklad, Madison, WI). Each dog will receive approximately 400g of feed over a minimum of 2 hours daily. Each lot of the feed will be analyzed to ensure that no contaminants are present at concentrations expected to interfere with the conduct or objectives of this study. Analytical data from the feed lots used in the study will be stored in a file at the laboratory. Dogs will be fasted before administration. Feed will be given approximately 1 hour after administration. Water. All dogs will be given free access to coarsely filtered Chicago city water via an automated watering system. The water will be regularly analyzed for bacterial contamination and chemical composition (e.g., electrolytes, metals, etc.). Records of the water analysis will be kept in a file at the testing facility. It is known that no contaminants expected to interfere with the study are present in the water. Animal identification. Each dog is identified by a USDA tattoo number on its right or left ear. Each dog is also assigned a unique number within the study. All cages are identified by project number, animal number, and sex. Cage cards are color-coded by group. Environmental control. The temperature and relative humidity of the animal enclosures are manually recorded daily. A 12-hour light / dark cycle (maintained by an automatic timer) is used. The animal enclosures are kept at a temperature of approximately 20°C to 25°C and a relative humidity of 30% to 70%, respectively.
[0152] method: Quarantine. Animals purchased for this study will be quarantined for at least two weeks before being administered the test substance. Throughout the quarantine period, the animals will be observed at least once a day for evidence of death or near-death. Randomization. After releasing the animals from quarantine, they are randomly assigned to groups. Prior to randomization, each dog undergoes detailed clinical observation to ensure its suitability as a test animal. Administration. Groups 1 and 2 will be administered a single oral capsule of 20 mg of BHV-3500 per dog. Groups 4 and 6 will be administered a single oral capsule of 50 mg of BHV-3500 per dog. Each group will be given a drug-free period of at least 48 hours before the next group is administered. Observation of mortal / death. Before initiating administration, observe animals for evidence of death or mortal status at least once daily. At the start of administration and throughout the remaining observation period, observe all surviving study animals at least twice daily to assess their overall health status and for evidence of death or mortal status. Record any abnormal clinical signs. Allow at least 4 hours between mortal / death checks. Dying animals. Any animal that is deemed unlikely to survive until the next scheduled observation period during the dying / death observation period will be removed from the study, weighed, euthanized, and autopsyed, with the consent of the assigned veterinarian and principal investigator. These animals will be recorded in the research notes as having been euthanized in imminent danger. Deceased animals will be immediately removed for autopsy and their death will be recorded in the research notes. Injured or sick animals. Animals in the study will be treated for any illness or injury in accordance with standard veterinary practice. The condition and characteristics of any affected animals will be fully documented in the research notebook. Any animals that pose a potential infection threat to other studies will be isolated. Clinical observation. Clinical observation should be performed approximately one hour after each dose is administered. Weight management. Measure the animal's weight before each dose. Measurement of feed consumption. In this study, the feed consumption of individual animals will not be measured. Plasma drug levels. Blood samples (approximately 3 mL collected from the jugular vein) are obtained from each dog at six time points after each dose (before administration, 15 minutes, 30 minutes, and 60 minutes, 2 hours, and 4 hours) to determine the plasma level of BHV-3500. EDTA is used as an anticoagulant. Plasma samples are frozen at approximately -70°C until the concentration of BHV-3500 is analyzed at the testing laboratory. AUC and t are used for pharmacokinetic modeling. 1 / 2 , T max , and C max It includes. Autopsy. This is a non-end-of-life study. The dog is returned to quarantine after its final blood draw. Data Notebook. All original paper data created at the examination center will be stored in a loose-leaf notebook. The paper data to be stored in the loose-leaf notebook includes, but is not limited to, the following: • The original signed protocol and all modifications and / or changes; • Record of receipt of animals; • Animal breeding records; • Test sample data; • Blood sample data; TK Data Data acquired electronically using ToxData® (e.g., dose administration, daily near-death / death and environmental data, clinical observations, body weight, etc.) will be stored in a computer system database. An electronic copy of the ToxData®.htm file will also be backed up to a CD-ROM, and the disk will be kept along with the raw data. Design changes. Protocol changes may occur as the research progresses, in the form of protocol modifications. Protocol changes will not be made without the explicit written consent of the research sponsor. Regulatory Standards and Compliance. Due to the experimental nature of this study, it will not be conducted in accordance with the U.S. FDA's Good Research Practices (GLP) regulations (Title 21, Part 38 of the Code of Enforcement Regulations). The study will be conducted according to the standard operating procedures of the testing center. Report. A draft of the report will be prepared and submitted to the research sponsor for review. The report will include, but is not limited to, the following: • A copy of the approved protocol, including all modifications and / or changes. • Species and strains of animals used • Clinical observation data • Weight data • Plasma drug level data • Pharmacokinetic data Following the client's review of the draft report, the final report will be submitted to the client. Data Retention. All raw data produced as a result of this study and copies of the final study report will be stored at the Test Center for one year from the date of completion of the study. The sponsor is responsible for all costs associated with the continued storage of archival materials in the Test Center's archives or their transportation to other storage facilities. The Test Center's QAU will maintain complete records of the disposal of all archival materials. Staff. The resumes of all staff members of the testing center who were involved in conducting the research will be kept at the testing center. Protocol approval. This protocol conforms to the specific documents of the research sponsor.
[0153] method 1. Experimental design and dosage administration For each group, three female beagle dogs were given a single dose of either BHV-3500 or FC-10475, as detailed in Table 1:
[0154] [Table 1]
[0155] 2.Blood collection After each dose, blood samples (approximately 3 mL from the jugular vein) were obtained from each dog at six time points (before administration, and at 15, 30, and 60 minutes, as well as 2 and 4 hours after administration) to determine the plasma level of BHV-3500. EDTA was used as an anticoagulant. Plasma samples were frozen at approximately -70°C until analysis.
[0156] 3. Preparation of reference and internal standards and plasma samples: Reference standards for BHV-3500 and BHV-3500-d8 were provided by the sponsor and stored at room temperature. These standards were used without further purification to determine the BHV-3500 concentration in plasma samples collected during this study and to prepare quality control (QC) samples.
[0157] To measure BHV-3500 in plasma, a fixed volume of 50 μL from each sample was transferred to a suitable well of a 96-well plate. 10 μL of water containing 50% acetonitrile (ACN) was added, followed by 250 μL of internal standard solution (BHV-3500-d8 in 10 ng / mL ACN). The plate was sealed and vortexed for approximately 5 minutes, then centrifuged at 4000 rpm for 10 minutes at 4±4°C. A portion of the resulting supernatant (100 μL) was transferred to a suitable well of another 96-well plate (containing 300 μL of water with 0.15% formic acid). This plate was sealed, and the contents were mixed before instrumental analysis.
[0158] The newly prepared BHV-3500 standard curve and QC samples were analyzed together with the study samples. Instrumental calibrators were prepared by adding 10 μL of BHV-3500 / FC-10475 stock solution to 50 μL of blank canine plasma. The blank canine plasma was supplied from BioIVT (Hicksville, NY) and stored frozen at -20°C. The nominal calibrator concentrations ranged from 2.00 to 200 ng / mL. QC samples were prepared at concentrations of 6.00, 50.0, and 150 ng / mL. The calibrators and QC samples were processed for analysis according to the extraction procedure described above.
[0159] 4. Analytical Instruments and Conditions Calibration materials, QCs, and research samples were analyzed under the LC-MS / MS instrument conditions detailed in Table 2. The calibration curve was a linear regression of the ratio of peak areas of the analyte and the internal standard to the analyte concentration (weighting coefficient 1 / x). 2 The concentration of the analyte in the sample was determined using the peak area ratio and regression parameters of the calibration curve.
[0160] [Table 2-1]
[0161] [Table 2-2]
[0162] 5. Pharmacokinetics Plasma BHV-3500 concentration data from individual animals at the scheduled (nominal) sampling time were analyzed using Phoenix WinNonlin software (version 8.1; Certara, Princeton, NJ) with a non-compartment model for extravascular administration.
[0163] constant value of excretion rate (λ z Where data allowed, the plasma excretion half-life (t) was calculated by log-linear regression at terminal phase data points (using the best-fit lambda Z calculation option in Phoenix WinNonlin).1 / 2 ) is ln(2) / λ z The calculation was performed using the area under the plasma concentration-time curve (AUC) for concentrations at 0 to 4 hours. 0~4時間 The result was calculated using the linear up / logdown trapezoidal rule.
[0164] Nominal dose levels were used for PK analysis. The following PK parameters were evaluated (where applicable and where data allowed). • Half-life of excretion (t 1 / 2 ) • Time to reach peak plasma concentration (T max ) ·Maximum plasma concentration (C max ) • Area under the plasma concentration-time curve [at 0-4 hours; AUC] 0~4時間 ]
[0165] The abbreviations and units for PK are shown in Table 3.
[0166] [Table 3]
[0167] result The determination of the BHV-3500 concentration is shown in Table 4 and graphically in Figure 1. The PK parameters are shown in Table 5 (BHV-3500).
[0168] [Table 4]
[0169] [Table 5]
[0170] Group 1, which received BHV-3500 along with DDM, was C max However, the level was 37.0 ng / mL compared to 31.7 ng / mL when BHV-3500 was administered without DDM (C max (A 16% increase).
[0171] In Group 1, where BHV-3500 was administered with DDM, the AUC was 55.1 hours*ng / mL compared to 44.4 hours*ng / mL in the group where BHV-3500 was administered without DDM (a 24% increase in AUC).
[0172] (Example 2) The purpose of the study described in this example was to evaluate the technical feasibility of formulating BHV-3500 into the Zydis® dosage form. Based on feasibility, the maximum dose strength was determined to be 50 mg of free base, which corresponds to 52.85 mg of hydrochloride (salt equivalence coefficient: 1.057).
[0173] The formulation feasibility study consisted of five manufacturing studies in an attempt to develop a robust formulation containing BHV-3500 and dodecylmaltoside that possessed acceptable key quality characteristics such as a satisfactory final product appearance and dispersion time.
[0174] Research 1 Study 1 consisted of five batches. Each batch contained a constant concentration of gelatin, mannitol, and dodecyl maltoside. Study 1 investigated the following: • Determination of the maximum achievable dose of BHV-3500 that can be formulated into a Zydis® unit. Evaluation of four types of wet-filled formulations with weights of 250 mg / 500 mg and 300 mg / 600 mg (dose-proportional formulations), as well as five concentrations (w / w%) of BHV-3500. Evaluation of dodecyl maltoside (0.50 w / w%) as a permeation enhancer that aids in API absorption. • The pH has been changed to pH 5.0 ± 0.2.
[0175] In most batches, the overall appearance of the final product was acceptable, and we were successful in freezing and lyophilizing higher-than-expected doses of BHV-3500 (17.62 w / w%). Extensive feathering was present in all batches, with the wet-fill weight (500 mg / 600 mg) batches showing a higher level of feathering.
[0176] Furthermore, splashing was identified as a problem, particularly in units with high concentrations of BHV-3500 and large wet-fill weights (batch Z4840 / 94 / 5a and 5b, with 16.67 w / w% API at wet-fill weights of 300 mg and 600 mg respectively).
[0177] All batches had a variance time of 10 seconds or less, which is within the acceptable limit.
[0178] It was suggested that the concentrations of matrix-forming agents such as gelatin and mannitol should be optimized to improve the appearance of the final product, the robustness of the units, and reduce feathering / fragility and ejection. Furthermore, the range of the permeability enhancer dodecyl maltoside should be defined to confirm its impact on the overall appearance of the final product.
[0179] Research 2 The objective of Study 2 was to optimize a formulation containing 16.67 w / w% BHV-3500 to improve its physical appearance and rigidity. Study 2 investigated the following: • Evaluation of the incorporation of various levels of the permeability enhancer dodecylmaltoside (0.2-0.5 w / w%). Evaluation of two different filling weights: 300 mg / 600 mg (proportional dosage formulation). Evaluation of HMW fish gelatin concentration (5.50-6.00 w / w%) and mannitol (4.40-4.80 w / w%). • The pH has been changed to pH 5.0 ± 0.2.
[0180] All batches produced had very high rates of cracking and detachment, and therefore dispersion testing was not performed. Based on the low quality of all batches produced, further formulation optimization was needed to improve the appearance and quality of the product. Increasing the amounts of gelatin and mannitol did not improve the appearance. Therefore, glycine was used as a potential structural enhancer. The concentration of DDM used as a potential permeability enhancer also needed to be optimized in the next study. Furthermore, it was recommended that the pH not be changed in future studies in order to determine the effect of citric acid on the appearance of the final product.
[0181] Research 3 The objective of Study 3 was to optimize formulations containing 16.67 w / w% and 0.50 w / w% BHV-3500 to improve their physical appearance and rigidity. Study 3 investigated the following: Evaluation of the incorporation of glycine (1.50% w / w) as a structural strengthening agent. • Evaluation of one type with a wet-fill weight of 600 mg. • No pH adjustment required.
[0182] Overall, all batches produced in Study 3 exhibited varying levels of cracking, clearly indicating that the presence of glycine did not help reduce cracking. No improvement was observed in either the batches with or without DDM.
[0183] All units produced in this study flew out of the indentation when the tray was turned over. Furthermore, the dispersion time of the units containing both DDM and glycine (batch Z4840 / 104 / 1) was outside the acceptable limit of 10 seconds, and the appearance of this batch was the worst of all batches. This suggested that the combination of DDM and glycine should not be pursued in future studies.
[0184] The oven study showed no changes in the assay or related substances during the period from day 0 to day 14. A rapid change occurred between day 14 and day 21, which was due to an inadvertent temperature deviation by raising the oven temperature to 105°C. After lowering the oven temperature to 50°C, there were no changes in the assay or related substances.
[0185] It was suggested that the next feasibility study should aim to determine the w / w% range of DDM and gelatin to aid in cracking, and to evaluate the impact on the appearance of the final product by reducing the dose of BHV-3500. This should be implemented as part of the experimental design.
[0186] Research 4 The objective of Study 4 was to modify HMW fish gelatin while maintaining the mannitol ratio and varying the DDM concentration, and to evaluate the effect of filling weight and solution retention time on the appearance of the final product as part of an experimental design study. A larger indentation size was also used to reduce the concentration of BHV-3500. Study 4 investigated the following: • HWM fish gelatin w / w% • w / w% of HWM DDM • No pH adjustment Place the 50mg / 100mg dose into the 600mg / 1200mg indentation.
[0187] This study demonstrated that increasing the dose and unit size from 50 mg dose / 600 mg indentation size to 100 mg dose / 1200 mg indentation size had a significant effect on the overall appearance and dispersion of the units at the same API concentration. Units with a 100 mg dose / 1200 mg indentation size also showed increased pop-out and cracking. DDM appeared to have a negative effect on the dispersion time of the units at higher concentrations of 0.5 w / w%. Therefore, a lower concentration of 0.25% DDM (w / w) and a filling weight of 600 mg were adopted for further formulation optimization studies.
[0188] Research 5 The objective of Study 5 was to produce a successful batch of Study 4 containing 0.25 w / w% DDM and 5.00 w / w% HMW fish gelatin to obtain samples for informal stability studies. Units without DDM were also produced to compare the effect of DDM on the appearance of the final product. Study 5 investigated the following: • Evaluation of the effects of 0.25 w / w% dodecyl maltoside.
[0189] All batches were successfully incorporated into the Zydis® matrix, producing white, circular units with good appearance and dispersion. Both batches of mixture Z4840 / 120 / 1~2 were reported to become cloudy when left standing with agitation for 24 hours; however, image examination revealed that the appearance of the solution remained unchanged throughout the 24-hour holding period, thus indicating stability. This was also confirmed by assay and related substance testing, where the units exhibited identical assay results at 24-hour solution hold, with no difference in related substances or quantities observed at both time points, demonstrating continued informal stability.
[0190] Batch Z4840 / 120 / 1, containing 0.25 w / w% DDM, showed no significant defects compared to batch Z4840 / 120 / 2, which did not contain DDM. This suggests that DDM at this concentration does not significantly affect the overall appearance of the final product.
[0191] However, batch Z4840 / 120 / 1 contained air bubbles within the units, while batch Z4840 / 120 / 2 did not. This suggests that the presence of DDM in the mixture increased viscosity, thus causing air bubbles during dispensing. However, given the small batch size and manual dispensing process, this is not considered a significant defect and will likely be optimized for larger batches in the future.
[0192] Formulation and design space Table 6 shows the formulation details evaluated during these studies. Ranges were defined for API concentration, gelatin and mannitol levels, dose weight, and permeability enhancer (dodecyl maltopyranoside). Further evaluation of formulation and process parameters is recommended during formulation optimization.
[0193] [Table 6]
[0194] Container stopper system Table 7 shows the packaging materials used in all studies.
[0195] [Table 7]
[0196] Technical Risk Assessment The findings obtained during these studies were used to update the technical risk assessment. Table 8 summarizes the findings.
[0197] [Table 8]
[0198] Residual solvent Table 9 shows the residual solvent evaluation of Zydis® BHV-3500 during the feasibility development stage.
[0199] [Table 9]
[0200] summary Based on the final product testing results of Study 5 and taking into account customer feedback, we recommend manufacturing batch Z4840 / 120 / 1 containing 0.25 w / w% DDM on a larger scale (approximately 5 kg) before bench-scale clinical manufacturing to ensure the manufacturability of the formulation.
[0201] This formulation may be suitable for technical batch / clinical GMP manufacturing, but further optimization / product characterization is strongly recommended after initial human trials.
[0202] Throughout this application, various publications are referenced by author name and date, or by patent number or patent publication number. The disclosures of these publications are incorporated into this application by reference in whole to better illustrate the current art known to those skilled in the art as of the date of the invention described herein and claimed. However, the reference of references herein should not be construed as an admission that such references are prior art to the present invention.
[0203] Those skilled in the art will recognize, or can verify by simply using routine experiments, many equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of the invention and are encompassed within the appended claims. For example, pharmaceutically acceptable salts other than those specifically disclosed herein can be employed. Furthermore, specific items within the list of items, or subsets of items within larger groups of items, are intended to be combined with other specific items, subsets of items, or larger groups of items, whether or not there is a specific disclosure herein that identifies such combinations.
Claims
1. calcitonin gene-related peptide (CGRP) inhibitors, wherein said CGRP inhibitor is zabegepant, rimegepant, ubrogepant, atogepant, telcagepant, or olcegepant; an absorption-enhancing amount of a carbohydrate surfactant, wherein the carbohydrate surfactant comprises an alkyl glycoside; In the form of an oral fast dispersing dosage form, Pharmaceutical compositions.
2. 10. The pharmaceutical composition of claim 1, further comprising a carrier, a filler and a flavoring agent.
3. 2. The pharmaceutical composition of claim 1, wherein the alkyl glycoside comprises a carbohydrate attached to a C10-C16 alkyl chain through a glycosidic bond.
4. The pharmaceutical composition of claim 3, wherein the carbohydrate surfactant is an alkyl glycoside, the alkyl glycoside having a hydrophilic-lipophilic balance value in the range of about 10 to 20.
5. The pharmaceutical composition according to claim 3 or 4, wherein the carbohydrate is maltose or sucrose.
6. A pharmaceutical composition described in any one of claims 3 to 5, wherein the carbohydrate surfactant is an alkyl glycoside, and the alkyl glycoside is a D-alkyl glycoside.
7. 7. The pharmaceutical composition of any one of claims 1 to 6, wherein the CGRP receptor antagonist is zavegepant and the alkyl glycoside is dodecyl D-β-maltoside.
8. 8. The pharmaceutical composition of claim 1, further comprising a mucosal delivery enhancer.
9. The pharmaceutical composition of claim 3, wherein the carbohydrate surfactant is an alkyl glycoside and the concentration of the alkyl glycoside is from about 0.05% w / v to 20% w / v.
10. A pharmaceutical composition according to any one of claims 1 to 9 for increasing the bioavailability of a calcitonin gene-related peptide (CGRP) inhibitor.
11. 10. A pharmaceutical composition according to any one of claims 1 to 9 for treating or preventing a condition associated with abnormal levels of CGRP.
